Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Crossref DOI link: https://doi.org/10.1186/s13075-015-0841-9
Published Online: 2015-11-15
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Weinblatt, Michael E.
Fleischmann, Roy
van Vollenhoven, Ronald F.
Emery, Paul
Huizinga, Tom WJ
Cutolo, Maurizio
van der Heijde, Désirée
Duncan, Benjamin
Davies, Owen
Luijtens, Kristel
Dougados, Maxime
Funding for this research was provided by:
UCB Pharma